243 related articles for article (PubMed ID: 34823106)
1. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
Nowak AK; Chin WL; Keam S; Cook A
Lung Cancer; 2021 Dec; 162():162-168. PubMed ID: 34823106
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND; Mansfield AS
Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
[TBL] [Abstract][Full Text] [Related]
3. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
5. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.
Assié JB; Jean D
Expert Opin Ther Targets; 2023; 27(11):1059-1069. PubMed ID: 37902459
[TBL] [Abstract][Full Text] [Related]
6. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
7. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
8. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
9. [Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma].
Huang Y; Meng Q
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):441-446. PubMed ID: 34157803
[TBL] [Abstract][Full Text] [Related]
10. Unprecedented long-term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo- and immunotherapeutic regimens.
Cerbone L; Delfanti S; De Angelis AM; Crivellari S; Boccuzzi F; Cimorelli A; Bertolotti M; Righi L; Bertino P; Grosso F
Thorac Cancer; 2023 Feb; 14(5):524-527. PubMed ID: 36599413
[TBL] [Abstract][Full Text] [Related]
11. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
12. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
Gray SG
BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
[TBL] [Abstract][Full Text] [Related]
13. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Hu ZI; Ghafoor A; Sengupta M; Hassan R
Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
[TBL] [Abstract][Full Text] [Related]
14. Management of Advanced Pleural Mesothelioma-At the Crossroads.
Nowak AK; Jackson A; Sidhu C
JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy.
Ripley RT; Mansfield AS; Sepesi B; Bueno R; Burt BM
J Thorac Cardiovasc Surg; 2023 Jan; 165(1):364-368. PubMed ID: 35221030
[No Abstract] [Full Text] [Related]
16. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
Remon J; Reguart N; Corral J; Lianes P
Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
18. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors.
Martella S; Aiello MM; Bertaglia V; Cau R; Denaro N; Cadoni A; Novello S; Scartozzi M; Novello G; Soto Parra HJ; Saba L; Solinas C; Porcu M
Target Oncol; 2024 Jan; 19(1):13-28. PubMed ID: 38063957
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
20. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]